These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

622 related items for PubMed ID: 27571885

  • 1. Chemotherapy for adult low-grade gliomas: clinical outcomes by molecular subtype in a phase II study of adjuvant temozolomide.
    Wahl M, Phillips JJ, Molinaro AM, Lin Y, Perry A, Haas-Kogan DA, Costello JF, Dayal M, Butowski N, Clarke JL, Prados M, Nelson S, Berger MS, Chang SM.
    Neuro Oncol; 2017 Feb 01; 19(2):242-251. PubMed ID: 27571885
    [Abstract] [Full Text] [Related]

  • 2. NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide.
    Wick W, Hartmann C, Engel C, Stoffels M, Felsberg J, Stockhammer F, Sabel MC, Koeppen S, Ketter R, Meyermann R, Rapp M, Meisner C, Kortmann RD, Pietsch T, Wiestler OD, Ernemann U, Bamberg M, Reifenberger G, von Deimling A, Weller M.
    J Clin Oncol; 2009 Dec 10; 27(35):5874-80. PubMed ID: 19901110
    [Abstract] [Full Text] [Related]

  • 3. IDH1 or IDH2 mutations predict longer survival and response to temozolomide in low-grade gliomas.
    Houillier C, Wang X, Kaloshi G, Mokhtari K, Guillevin R, Laffaire J, Paris S, Boisselier B, Idbaih A, Laigle-Donadey F, Hoang-Xuan K, Sanson M, Delattre JY.
    Neurology; 2010 Oct 26; 75(17):1560-6. PubMed ID: 20975057
    [Abstract] [Full Text] [Related]

  • 4. Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study.
    Baumert BG, Hegi ME, van den Bent MJ, von Deimling A, Gorlia T, Hoang-Xuan K, Brandes AA, Kantor G, Taphoorn MJB, Hassel MB, Hartmann C, Ryan G, Capper D, Kros JM, Kurscheid S, Wick W, Enting R, Reni M, Thiessen B, Dhermain F, Bromberg JE, Feuvret L, Reijneveld JC, Chinot O, Gijtenbeek JMM, Rossiter JP, Dif N, Balana C, Bravo-Marques J, Clement PM, Marosi C, Tzuk-Shina T, Nordal RA, Rees J, Lacombe D, Mason WP, Stupp R.
    Lancet Oncol; 2016 Nov 26; 17(11):1521-1532. PubMed ID: 27686946
    [Abstract] [Full Text] [Related]

  • 5. Impact of 1p/19q codeletion and histology on outcomes of anaplastic gliomas treated with radiation therapy and temozolomide.
    Speirs CK, Simpson JR, Robinson CG, DeWees TA, Tran DD, Linette G, Chicoine MR, Dacey RG, Rich KM, Dowling JL, Leuthardt EC, Zipfel GJ, Kim AH, Huang J.
    Int J Radiat Oncol Biol Phys; 2015 Feb 01; 91(2):268-76. PubMed ID: 25636755
    [Abstract] [Full Text] [Related]

  • 6. Temozolomide during and after radiation therapy for WHO grade III gliomas: preliminary report of a prospective multicenter study.
    Kim YH, Park CK, Cho WH, Kim IA, Moon S, Choe G, Park SH, Kim IH, Kim DG, Jung HW, Lee MM, Bae SH, Cha SH, Kim CY.
    J Neurooncol; 2011 Jul 01; 103(3):503-12. PubMed ID: 20862518
    [Abstract] [Full Text] [Related]

  • 7. Efficacy and patient-reported outcomes with dose-intense temozolomide in patients with newly diagnosed pure and mixed anaplastic oligodendroglioma: a phase II multicenter study.
    Ahluwalia MS, Xie H, Dahiya S, Hashemi-Sadraei N, Schiff D, Fisher PG, Chamberlain MC, Pannullo S, Newton HB, Brewer C, Wood L, Prayson R, Elson P, Peereboom DM.
    J Neurooncol; 2015 Mar 01; 122(1):111-9. PubMed ID: 25534576
    [Abstract] [Full Text] [Related]

  • 8. Efficacy of initial temozolomide for high-risk low grade gliomas in a phase II AINO (Italian Association for Neuro-Oncology) study: a post-hoc analysis within molecular subgroups of WHO 2016.
    Rudà R, Pellerino A, Pace A, Carapella CM, Dealis C, Caroli M, Faedi M, Bello L, Migliore E, Marchese G, Bertero L, Cassoni P, Soffietti R.
    J Neurooncol; 2019 Oct 01; 145(1):115-123. PubMed ID: 31556015
    [Abstract] [Full Text] [Related]

  • 9. Impact of 1p/19q codeletion status on extent of resection in WHO grade II glioma: Insights from a national cancer registry.
    Lu VM, Alvi MA, Bydon M, Quinones-Hinojosa A, Chaichana KL.
    Clin Neurol Neurosurg; 2019 Jul 01; 182():32-36. PubMed ID: 31063969
    [Abstract] [Full Text] [Related]

  • 10. The impact of adjuvant therapy for patients with high-risk diffuse WHO grade II glioma.
    Youland RS, Kreofsky CR, Schomas DA, Brown PD, Buckner JC, Laack NN.
    J Neurooncol; 2017 Dec 01; 135(3):535-543. PubMed ID: 28836106
    [Abstract] [Full Text] [Related]

  • 11. Observation versus radiotherapy with or without temozolomide in postoperative WHO grade II high-risk low-grade glioma: a retrospective cohort study.
    Wang J, Yan L, Ai P, He Y, Guan H, Wei Z, He L, Mu X, Liu Y, Peng X.
    Neurosurg Rev; 2021 Jun 01; 44(3):1447-1455. PubMed ID: 32529528
    [Abstract] [Full Text] [Related]

  • 12. MRI features predict survival and molecular markers in diffuse lower-grade gliomas.
    Zhou H, Vallières M, Bai HX, Su C, Tang H, Oldridge D, Zhang Z, Xiao B, Liao W, Tao Y, Zhou J, Zhang P, Yang L.
    Neuro Oncol; 2017 Jun 01; 19(6):862-870. PubMed ID: 28339588
    [Abstract] [Full Text] [Related]

  • 13. Temozolomide and 13-cis retinoic acid in patients with anaplastic gliomas: a prospective single-arm monocentric phase-II study (RNOP-05).
    Grauer O, Pascher C, Hartmann C, Zeman F, Weller M, Proescholdt M, Brawanski A, Pietsch T, Wick W, Bogdahn U, Hau P.
    J Neurooncol; 2011 Sep 01; 104(3):801-9. PubMed ID: 21373969
    [Abstract] [Full Text] [Related]

  • 14. Malignant Transformation of Molecularly Classified Adult Low-Grade Glioma.
    Tom MC, Park DYJ, Yang K, Leyrer CM, Wei W, Jia X, Varra V, Yu JS, Chao ST, Balagamwala EH, Suh JH, Vogelbaum MA, Barnett GH, Prayson RA, Stevens GHJ, Peereboom DM, Ahluwalia MS, Murphy ES.
    Int J Radiat Oncol Biol Phys; 2019 Dec 01; 105(5):1106-1112. PubMed ID: 31461674
    [Abstract] [Full Text] [Related]

  • 15. Radiation and chemotherapy for high-risk lower grade gliomas: Choosing between temozolomide and PCV.
    McDuff SGR, Dietrich J, Atkins KM, Oh KS, Loeffler JS, Shih HA.
    Cancer Med; 2020 Jan 01; 9(1):3-11. PubMed ID: 31701682
    [Abstract] [Full Text] [Related]

  • 16. Upfront Therapy of Aggressive/High-Risk Low-Grade Glioma: Single-Institution Outcome Analysis of Temozolomide-Based Radio-Chemotherapy and Adjuvant Chemotherapy.
    Anand S, Chatterjee A, Gupta T, Panda P, Moiyadi A, Epari S, Patil V, Krishnatry R, Goda JS, Jalali R.
    World Neurosurg; 2021 Oct 01; 154():e176-e184. PubMed ID: 34245877
    [Abstract] [Full Text] [Related]

  • 17. Analysis of IDH mutation, 1p/19q deletion, and PTEN loss delineates prognosis in clinical low-grade diffuse gliomas.
    Sabha N, Knobbe CB, Maganti M, Al Omar S, Bernstein M, Cairns R, Çako B, von Deimling A, Capper D, Mak TW, Kiehl TR, Carvalho P, Garrett E, Perry A, Zadeh G, Guha A, Sidney Croul.
    Neuro Oncol; 2014 Jul 01; 16(7):914-23. PubMed ID: 24470545
    [Abstract] [Full Text] [Related]

  • 18. Safety and efficacy of stereotactic radiosurgery and adjuvant bevacizumab in patients with recurrent malignant gliomas.
    Cuneo KC, Vredenburgh JJ, Sampson JH, Reardon DA, Desjardins A, Peters KB, Friedman HS, Willett CG, Kirkpatrick JP.
    Int J Radiat Oncol Biol Phys; 2012 Apr 01; 82(5):2018-24. PubMed ID: 21489708
    [Abstract] [Full Text] [Related]

  • 19. Adjuvant and concurrent temozolomide for 1p/19q non-co-deleted anaplastic glioma (CATNON; EORTC study 26053-22054): second interim analysis of a randomised, open-label, phase 3 study.
    van den Bent MJ, Tesileanu CMS, Wick W, Sanson M, Brandes AA, Clement PM, Erridge S, Vogelbaum MA, Nowak AK, Baurain JF, Mason WP, Wheeler H, Chinot OL, Gill S, Griffin M, Rogers L, Taal W, Rudà R, Weller M, McBain C, Reijneveld J, Enting RH, Caparrotti F, Lesimple T, Clenton S, Gijtenbeek A, Lim E, Herrlinger U, Hau P, Dhermain F, de Heer I, Aldape K, Jenkins RB, Dubbink HJ, Kros JM, Wesseling P, Nuyens S, Golfinopoulos V, Gorlia T, French P, Baumert BG.
    Lancet Oncol; 2021 Jun 01; 22(6):813-823. PubMed ID: 34000245
    [Abstract] [Full Text] [Related]

  • 20. A 25-year retrospective, single center analysis of 343 WHO grade II/III glioma patients: implications for grading and temozolomide therapy.
    Steidl E, Filipski K, Zeiner PS, Wagner M, Fokas E, Forster MT, Ronellenfitsch MW, Divé I, Steinbach JP, Harter PN, Bähr O.
    J Cancer Res Clin Oncol; 2021 Aug 01; 147(8):2373-2383. PubMed ID: 33538917
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 32.